Introduction
Helicobacter pylori infection remains a major cause of chronic gastritis, peptic ulcer, and gastric cancer, yet the efficacy of conventional eradication regimens is increasingly compromised by antibiotic resistance. Tegoprazan, a novel potassium-competitive acid blocker (P-CAB), offers rapid and sustained acid suppression with fewer pharmacokinetic limitations compared to proton pump inhibitors, making it a promising backbone for optimized eradication strategies. This prospective, randomized controlled trial aims to evaluate the efficacy and safety of tegoprazan-based dual, triple, and quadruple therapies as first-line treatments, providing evidence to guide optimal regimen selection in clinical practice.
Aims & Methods
This study aimed to assess the eradication rates, incidence of adverse events, and medication adherence of four different tegoprazan-based regimens as first-line therapy for H. pylori infection, and to explore the clinical value of adding bismuth to a triple therapy regimen. In this prospective, randomized controlled trial, 640 treatment-naive patients with confirmed H. pylori infection were randomly assigned to one of the four 14-day regimens. Group TA received tegoprazan tablets (50 mg) twice daily (30 min before breakfast and dinner) plus amoxicillin capsules (750 mg) four times daily (after breakfast, lunch, dinner, and at bedtime). Group TT received tegoprazan tablets 50 mg twice daily (30 min before breakfast and dinner) plus tetracycline tablets (500 mg) four times daily (after breakfast, lunch, dinner, and at bedtime). Group TAT received tegoprazan tablets 50 mg twice daily, amoxicillin capsules 1000 mg twice daily, and tetracycline tablets 500 mg three times daily, administered according to the schedules described above. Group TATB received the same regimen as Group TAT, with addition of bismuth potassium citrate capsules (300 mg, equivalent to 110 mg bismuth) twice daily (30 min before meals, taken concomitantly with tegoprazan), with 160 patients in each group. The primary outcomes were eradication rate, incidence of adverse events, and medication adherence.
Results
The H. pylori eradication rates in the TA, TT, TAT, and TATB groups were 80.0%, 61.9%, 93.1%, and 89.4%, respectively, in the intention-to-treat (ITT) analysis, with similar results in the modified ITT and per-protocol analyses. Overall differences among the four groups were statistically significant in the ITT analysis (P < 0.001). Compared with TATB, the TAT regimen was non‑inferior (95% CI, −3.9% to +11.5%; non‑inferiority P < 0.001), whereas TA and TT failed to demonstrate non-inferiority. Adverse events were less frequent in the TA (10.6%), TT (17.5%), and TAT (20.0%) groups than in the TATB group (36.9%; all P < 0.001). Adherence was high across groups, with no significant difference in discontinuation rates due to adverse events.
Conclusion
The tegoprazan-based triple regimen combining amoxicillin and tetracycline demonstrates high eradication efficacy, is non-inferior to the bismuth-containing quadruple regimen, and is associated with fewer adverse events. This simplified regimen may represent an effective first-line treatment option for H. pylori infection.